Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 with Gemcitabine and Radiotherapy in Pancreatic Cancer
NCT02910882Phase 2Terminated
- Sponsor
- Scripps Health
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegvorhyaluronidase alfa in pancreatic adenocarcinoma (PDAC), sponsored by Scripps Health. Primary endpoint: Number of Participants with Treatment Related Adverse Events. Started Jan 2017; status: terminated.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02910882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910882.